AstraZeneca Keeps R&D Focus, Spins Out Phase II Neuromyelitis Optica MAb Into New Biotech

 
• By John Davis
Vortex
Spinning off non-core assets has been a feature of AstraZeneca's business development • Source: Shutterstock

More from Immunological

More from Therapeutic Category